Section of Genetic Medicine, Department of Medicine, The University of Chicago, KCBD 3220D, 900 East 57th Street, Chicago, IL, 60637-1234, USA,
Hum Genet. 2014 Jun;133(6):679-87. doi: 10.1007/s00439-013-1411-3. Epub 2014 Jan 1.
Alternative splicing is a major cellular mechanism in metazoans for generating proteomic diversity. A large proportion of protein-coding genes in multicellular organisms undergo alternative splicing, and in humans, it has been estimated that nearly 90 % of protein-coding genes-much larger than expected-are subject to alternative splicing. Genomic analyses of alternative splicing have illuminated its universal role in shaping the evolution of genomes, in the control of developmental processes, and in the dynamic regulation of the transcriptome to influence phenotype. Disruption of the splicing machinery has been found to drive pathophysiology, and indeed reprogramming of aberrant splicing can provide novel approaches to the development of molecular therapy. This review focuses on the recent progress in our understanding of alternative splicing brought about by the unprecedented explosive growth of genomic data and highlights the relevance of human splicing variation on disease and therapy.
选择性剪接是后生动物产生蛋白质组多样性的主要细胞机制。在多细胞生物中,很大一部分蛋白质编码基因经历选择性剪接,据估计,在人类中,近 90%的蛋白质编码基因——比预期的要大得多——受到选择性剪接的影响。对选择性剪接的基因组分析揭示了它在塑造基因组进化、控制发育过程以及动态调节转录组以影响表型方面的普遍作用。已经发现剪接机制的破坏会导致病理生理学,事实上,异常剪接的重编程可以为分子治疗的发展提供新的方法。这篇综述重点介绍了基因组数据的空前爆炸式增长带来的我们对选择性剪接的理解的最新进展,并强调了人类剪接变异与疾病和治疗的相关性。